Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravenous BIIB093 for severe cerebral edema after large hemispheric infarction
MOH_2019-01-22_004742Phase 3Recruiting
- Sponsor
- Biogen
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke and cerebral edema comparing BIIB093 with Placebo (2 arms). Primary endpoint: Functional outcome improvement. Started Jul 2018; status: recruiting.
02
Drugs
glibenclamide
03
Conditions
ischemic strokecerebral edema
Beyond the preview
Go deeper on MOH_2019-01-22_004742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-22_004742.